CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Metformindrug
Likely dose
Metformin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05553704
NCT05553704Phase 2Completed
CompareCT.gov

Clinical Study to Compare the Possible Efficacy of Metformin in Patients With Ulcerative Colitis Treated With Mesalamine

Tanta University·interventional·Posted Sep 23, 2022·Updated Apr 8, 2025

In Brief

A Phase 2 clinical trial evaluating Metformin for Inflammatory Bowel Diseases. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease characterized by diffused inflammation of the colon and rectum mucosa, however, the exact underlying mechanisms of UC remain poorly understood.UC is strongly dependent on cellular immune reaction and exaggerated inflammatory response due to genetic, immune and environmental factors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Diseases
CountriesEgypt
CollaboratorsMounir Hussein Bahgat Internal Medicine Department Mansoura University, Maha Mohamed Maher Internal Medicine Department Mansoura University

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedSep 23, 2022
Enrollment StartNov 1, 2022
Primary CompletionMar 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 3.8 years ago

Interventions

Metformindrug

metformin group will take mesalamine 1 gm three times daily plus metformin 500 mg two times daily